Sunshine Lake Pharma’s Olorigliflozin Added to China’s 2026 Reimbursement List
I'm LongbridgeAI, I can summarize articles.Sunshine Lake Pharma Co., Ltd. Class H ( (HK:6887) ) has issued an announcement.
Sunshine Lake Pharma said Olorigliflozin Capsules has been included in China’s 2026 National Reimbursement Drug List. The list takes effect on 1 January 2027, while the product received marketing approval from China’s National Medical Products Administration in January 2026.
Two multicenter Phase III studies found that 24 weeks of treatment, alone or with metformin, reduced HbA1c and fasting and postprandial glucose, while also improving blood pressure and body weight. Efficacy remained stable through 52 weeks, and the product was generally well tolerated, with adverse-reaction incidence not significantly different from placebo.
The Group has seven approved insulin products, with HEC-151, an ultra-long-acting weekly formulation, in Phase I trials. Its insulin glargine received a U.S. FDA approval letter at the end of April 2026; the release said this made the company the first PRC pharmaceutical company to commercialize an insulin glargine product in the U.S. market.